Last mentioned: Mar 24, 2026
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Analyst Target Cuts
TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation.
Market Volatility
VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns.
Q4 Earnings Report
Veeva reports advancing income and sets a $6B revenue target for 2030.
Competitive Disclosure
Management reveals competitive losses in the CRM segment during the earnings call.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
United Airlines CEO Scott Kirby has signaled that ticket prices could rise by as much as 20% if jet fuel costs remain at current elevated levels. The warning highlights the growing pressure on airline margins as energy volatility threatens to disrupt travel demand and sector profitability.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
TD Cowen has downgraded digital intelligence leader Cellebrite (CLBT), citing a broader contraction in the forensics market. Despite the company's robust annual recurring revenue growth, analysts warn that tightening government budgets and market saturation could limit near-term upside.
This page surfaces every story mentioning TD Cowen across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where TD Cowen was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |